Literature DB >> 9442552

A case of serotonin syndrome caused by venlafaxine and lithium.

G Mekler1, B Woggon.   

Abstract

Serotonin syndrome occurred under treatment with average dose of Venlafaxine and lithium in a 50 year-old female patient with a history of sensitiveness to SSRIs. Plasma levels of Venlafaxine and its metabolite were within reference range. Parmacogenetic evaluation indicated normal metabolic pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9442552     DOI: 10.1055/s-2007-979507

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Serotonin Syndrome following Introduction of Venlafaxine following Withdrawal of Phenelzine: Implications for Drug Washout Periods.

Authors:  Sarah J Yates; Niraj Ahuja; Sarah E Gartside; R Hamish McAllister-Williams
Journal:  Ther Adv Psychopharmacol       Date:  2011-08

Review 3.  Differential pharmacokinetics of lithium in elderly patients.

Authors:  B A Sproule; B G Hardy; K I Shulman
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

4.  Delayed Onset and Prolonged ECT-Related Delirium.

Authors:  Sameer Hassamal; Ananda Pandurangi; Vasu Venkatachalam; James Levenson
Journal:  Case Rep Psychiatry       Date:  2013-09-03

5.  A case of the serotonin syndrome secondary to phenelzine monotherapy at therapeutic dosing.

Authors:  A Malik; N Junglee
Journal:  Case Rep Med       Date:  2015-03-16

6.  Prolonged Post-electroconvulsive Therapy Delirium: An Unusual Presentation.

Authors:  Ahmad R Khan; Hafsa Mahmood; Saad Wasiq; Hina Saeed
Journal:  Cureus       Date:  2018-08-28

7.  Venlafaxine in the treatment of panic disorder.

Authors:  Martin A Katzman; Leslie Jacobs
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

8.  Venlafaxine extended release (XR) in the treatment of panic disorder.

Authors:  Kevin Kjernisted; Diane McIntosh
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.